Clinical trial
A Phase II, Open Label, Multicenter Study of Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in Patients With EGFR Mutant Non-small Cell Lung Cancer Who Have Brain Metastases
NCT02655536 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open Label, Multicenter Study of Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in Patients With EGFR Mutant Non-small Cell Lung Cancer Who Have Brain Metastases
- Lead sponsor
- National Taiwan University Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 1, 2017
- Completion date
- December 31, 2019
- Enrollment
- 109 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.